merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>compounded drugs are subject to far less oversight</answer>
<question_number>2</question_number>
<answer>it allows patients to purchase directly from Lilly, bypassing telehealth companies</answer>
<question_number>3</question_number>
<answer>unique risks for older patients</answer>
<question_number>4</question_number>
<answer>to attract customers currently using cheaper compounded alternatives</answer>
<question_number>5</question_number>
<answer>it may limit the ability of compounding pharmacies to produce alternatives</answer>
<question_number>6</question_number>
<answer>removing third-party supply chain entities</answer>
<question_number>7</question_number>
<answer>patients may seek cheaper alternatives due to lack of coverage</answer>
<question_number>8</question_number>
<answer>it positions its vials as a safer option</answer>
<question_number>9</question_number>
<answer>in shortage</answer>
<question_number>10</question_number>
<answer>lower pricing for its own product</answer>